- Home
- TIL vs KOD Comparison
TIL vs KOD Comparison
Compare TIL & KOD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TIL
- KOD
- Stock Information
- Founded
- TIL 2018
- KOD 2009
- Country
- TIL United States
- KOD United States
- Employees
- TIL N/A
- KOD N/A
- Industry
- TIL Biotechnology: Pharmaceutical Preparations
- KOD Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- TIL Health Care
- KOD Health Care
- Exchange
- TIL Nasdaq
- KOD Nasdaq
- Market Cap
- TIL 170.7M
- KOD 186.3M
- IPO Year
- TIL 2021
- KOD 2018
- Fundamental
- Price
- TIL $21.17
- KOD $8.88
- Analyst Decision
- TIL Buy
- KOD Hold
- Analyst Count
- TIL 4
- KOD 5
- Target Price
- TIL $100.33
- KOD $6.80
- AVG Volume (30 Days)
- TIL 107.5K
- KOD 464.3K
- Earning Date
- TIL 11-13-2024
- KOD 11-14-2024
- Dividend Yield
- TIL N/A
- KOD N/A
- EPS Growth
- TIL N/A
- KOD N/A
- EPS
- TIL N/A
- KOD N/A
- Revenue
- TIL N/A
- KOD N/A
- Revenue This Year
- TIL N/A
- KOD N/A
- Revenue Next Year
- TIL $2.65
- KOD N/A
- P/E Ratio
- TIL N/A
- KOD N/A
- Revenue Growth
- TIL N/A
- KOD N/A
- 52 Week Low
- TIL $6.72
- KOD $2.19
- 52 Week High
- TIL $92.00
- KOD $11.60
- Technical
- Relative Strength Index (RSI)
- TIL 36.47
- KOD 65.85
- Support Level
- TIL $20.57
- KOD $8.03
- Resistance Level
- TIL $22.69
- KOD $9.18
- Average True Range (ATR)
- TIL 2.72
- KOD 0.86
- MACD
- TIL -0.23
- KOD -0.03
- Stochastic Oscillator
- TIL 2.98
- KOD 45.42
About TIL Instil Bio Inc.
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize FRα, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.
About KOD Kodiak Sciences Inc
Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is KSI-301, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD.